|
MechanismMyelin-oligodendrocyte glycoprotein expression stimulants |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Convelo Therapeutics, Inc.
0 Patents (Medical) associated with Convelo Therapeutics, Inc.
100 Deals associated with Convelo Therapeutics, Inc.
100 Translational Medicine associated with Convelo Therapeutics, Inc.